Hissar Syed S, Goyal Ankur, Kumar Manoj, Pandey Chandana, Suneetha P V, Sood Ajit, Midha Vandana, Sakhuja Puja, Malhotra Veena, Sarin Shiv K
Department of Gastroenterology & Advanced Center for Liver Diseases, GB Pant Hospital, Affiliated to the University of Delhi, New Delhi, India.
J Med Virol. 2006 Apr;78(4):452-8. doi: 10.1002/jmv.20561.
Hepatitis C virus (HCV) genotypes help to tailor the treatment response, but their influence on the disease severity and association with hepatic steatosis is not well understood. The prevalence of HCV genotypes and their correlation with the histopathological severity of liver disease and steatosis in Indian patients were studied. HCV-RNA and genotyping was carried out in 398 patients with chronic hepatitis C. Liver biopsy was available in 292 (73.4%) patients. The severity of liver disease was graded on the basis of the histological activity index and the stage of hepatic fibrosis. The patients were categorized as having mild (histological activity index < or =5 and/or fibrosis < or =2) or severe (histological activity index > or =6 and/or fibrosis > or =3) liver disease. Steatosis was graded in 106 patients as 0 (no steatosis), 1 (<33% of hepatocytes affected), 2 (33%-66% of hepatocytes affected), or 3 (>66% of hepatocytes affected). HCV genotype 3 was detected in 80.2% patients (3a:24.4%, 3b:3.3%, 3c:0.5%, 3a/3b:36.7%, and un-subtypable 3:15.3%), genotype 1 in 13.1% (1a:3%, 1b:5.5%, 1a/1b:0.3%, and un-subtypable 1:4.3%), genotype 4 in 3% patients (4a:1.5%, 4b:0.3%, 4a/4c:0.5%, and un-subtypable 4:0.8%), 2 in 2.5% and mixed genotypes (more than one genotype) in 1.3% of patients. The median histological activity index and fibrosis scores were: 5 and 2 in genotype 1; 4 and 2 in genotype 2; 5 and 2 in genotype 3; 7 and 3 in genotype 4; and 5 and 2 in mixed genotypes, respectively. Severe liver disease was present in 17 of 38 (45%) with genotype 1; in 1 of 3 (33%) with genotype 2; in 128 of 236 (54%) with genotype 3; 7 of 10 (70%) with genotype 4; and in 1 of 4 (25%) with mixed genotype. Hepatic steatosis grade > or =2 was found in 28.1% of genotype 3; 23.5% of genotype 1; 20% of genotype 4; and in none of genotype 2 and mixed genotypes. In conclusion, genotype 3 is the most prevalent genotype in patients with chronic hepatitis C in North and Central India and this is associated with significant hepatic steatosis and fibrosis.
丙型肝炎病毒(HCV)基因型有助于调整治疗反应,但其对疾病严重程度的影响以及与肝脂肪变性的关联尚不清楚。本研究旨在探讨印度患者中HCV基因型的流行情况及其与肝脏疾病组织病理学严重程度和脂肪变性的相关性。对398例慢性丙型肝炎患者进行了HCV-RNA检测和基因分型。292例(73.4%)患者进行了肝活检。根据组织学活动指数和肝纤维化分期对肝脏疾病的严重程度进行分级。患者被分为轻度(组织学活动指数≤5和/或纤维化≤2)或重度(组织学活动指数≥6和/或纤维化≥3)肝病。对106例患者的脂肪变性进行分级,分为0级(无脂肪变性)、1级(<33%的肝细胞受累)、2级(33%-66%的肝细胞受累)或3级(>66%的肝细胞受累)。80.2%的患者检测到HCV基因型3(3a:24.4%,3b:3.3%,3c:0.5%,3a/3b:36.7%,不可分型3:15.3%),13.1%的患者检测到基因型1(1a:3%,1b:5.5%,1a/1b:0.3%,不可分型1:4.3%),3%的患者检测到基因型4(4a:1.5%,4b:0.3%,4a/4c:0.5%,不可分型4:0.8%),2.5%的患者检测到基因型2,1.3%的患者检测到混合基因型(不止一种基因型)。基因型1、2、3、4和混合基因型的组织学活动指数和纤维化评分中位数分别为:5和2、4和2、5和2、7和3以及5和2。基因型1的38例患者中有17例(45%)患有重度肝病;基因型2的3例患者中有1例(33%);基因型3的236例患者中有128例(54%);基因型4的10例患者中有7例(70%);混合基因型的4例患者中有1例(25%)。在基因型3的患者中,28.1%的患者肝脂肪变性分级≥2级;基因型1的患者中为23.5%;基因型4的患者中为20%;基因型2和混合基因型的患者中均未发现。总之,基因型3是印度北部和中部慢性丙型肝炎患者中最常见的基因型,且与显著的肝脂肪变性和纤维化相关。